Terminated cancer drug trial tested only 3 patients

NCT ID NCT06509906

Terminated Disease control Sponsor: EMD Serono Research & Development Institute, Inc. Source: ClinicalTrials.gov ↗

Summary

This early-stage study tested the safety of a new drug called M9466 when combined with standard chemotherapy drugs for advanced solid tumors and colorectal cancer. The trial aimed to find the highest safe dose and see if the combination showed any anti-cancer activity. Only 3 participants were enrolled before the study was terminated.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Cancer Research SA

Elizabeth Vale, Australia
Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center

Pennington, New Jersey, 08534, United States
NEXT Barcelona - NEXT Barcelona

Barcelona, Spain
NEXT Madrid - Hospital Universitario Quironsalud Madrid

Pozuelo de Alarcón, Spain
National Cancer Center Hospital

Chūōku, Japan
Peter MacCallum Cancer Centre - Use the one with Account 2 VCCC

Parkville, Australia
Samsung Medical Center

Seoul, South Korea
Sarah Cannon Research Institute at Health One

Denver, Colorado, 80218, United States
Seoul National University Hospital

Seoul, South Korea
St George Private Hospital

Kogarah, Australia
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030-4009, United States
Vanderbilt University - 150912667

Nashville, Tennessee, 37232, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMOR